Is Telehealth a High-Risk Business for Payment Processors? What Moves You Into, and Out of, High Risk
Telehealth isn't one risk class. What you sell sets the category, and how you sell it decides how you're underwritten inside it.
It depends on what you sell. Visa has no telehealth category, so a consult-only practice and a company that ships prescriptions are underwritten very differently. Selling prescription drugs non-face-to-face puts you in a category that is high-integrity risk on our reading of Visa's rules, and that Mastercard registers according to acquirer notices; compounded GLP-1s, controlled substances, subscriptions, prepaid plans and aggressive marketing add more. Some of that you can change. The category itself you can't.
A high-risk merchant account is industry shorthand for card acceptance that an acquirer underwrites under stricter terms because the business's category, model or history carries more exposure to disputes, fraud, regulatory action or brand damage. For prescription sales the networks have their own terms: high-integrity risk at Visa and, according to acquirer notices, Specialty Merchant Registration at Mastercard.
Is telehealth high risk?
Some telehealth is and some isn't, and the line runs through what the patient pays you for. Neither of Visa's October 2026 manuals mentions telehealth; the merchant category code follows what is sold. Our reading of where five models sit:
| Model | Where it sits, in our reading | Why |
|---|---|---|
| Consult-only services without prescriptions, such as therapy billed per session | Generally lower risk | A practitioner code such as 8099 and no drug sales |
| Consults that lead to prescriptions, with the pharmacy charging the patient for the medication | Depends on billing and marketing | Your account carries the care; the pharmacy's account carries the drug |
| A membership or bundle that includes medication you charge for | High-integrity risk at Visa | You are selling prescription drugs non-face-to-face, under MCC 5912 |
| Compounded GLP-1 programs | High-integrity risk, plus product-level questions | FDA's shortage decisions, its position on salt forms, its warning letters |
| Controlled-substance prescribing | Elevated, with a date attached | DEA's telemedicine flexibilities run through December 31, 2026 |
"Generally lower" is not "low". A therapy practice with prepaid packages and a hard-to-find cancel button can still generate the disputes that make any account hard to keep.
What moves a telehealth business into high risk?
Six things, and they stack.
Selling prescription drugs
Section 1.9.5.1 of Visa's rules spares accredited merchants under 5122 and 5912 from registration as high-integrity risk merchants. We read that exemption as meaning non-face-to-face pharmaceutical sales are high-integrity risk to begin with, which brings acquirer registration and daily monitoring. Acquirer notices describe Mastercard registering the same category under its Specialty Merchant Registration program from July 24, 2026 for most categories in the US.
Compounded GLP-1s
FDA declared the tirzepatide and semaglutide shortages resolved, and its transition periods for compounders ended in 2025. FDA's position is that compounders can no longer rely on the shortage to make essentially copies, and it has issued warning letters to telehealth sellers over their marketing. Underwriters respond with product-by-product questions about the pharmacy and the active ingredient.
Controlled substances
DEA's fourth temporary extension of its COVID-19 telemedicine flexibilities (Federal Register, December 31, 2025) runs through December 31, 2026. Without it, the Ryan Haight Act default generally requires at least one in-person medical evaluation before a controlled substance is prescribed remotely. DEA proposed a special-registration rule on January 17, 2025 (90 FR 6541), including a telemedicine platform registration; a final rule went to OIRA, as reported on August 25, 2026, and had not been published as of mid-November 2026 per our search. Testosterone, ketamine and buprenorphine are Schedule III; amphetamine and methylphenidate are Schedule II. Expect questions about which you prescribe, your prescribers' DEA registrations, and your plan for January 1, 2027.
Subscriptions and prepaid plans
Recurring billing brings Visa's 13.2 cancelled-recurring disputes. Prepaid multi-month plans collect money before the service or medication is delivered, which is the exposure a reserve exists to cover; how that works is in why processors hold reserves on telehealth accounts.
Marketing claims
FDA's warning letters cited "same active ingredient" claims, and the FTC alleged in its NextMed case (settled July 2025) unsupported weight-loss claims and fake testimonials. Visa can act against "illegal or brand-damaging" transaction activity under §1.9.1.4, so the acquirer reads your ads.
Dispute history
Acquirers and chargeback vendors report that Visa's VAMP threshold for merchants fell to 1.5% on April 1, 2026 in the US. A history near that line follows you into every application.
What does being high risk change in practice?
More paperwork before you go live and closer monitoring afterwards. For a high-integrity risk merchant under Visa's rules:
- the acquirer must hold Visa's high-integrity risk acquiring registration and register you, unless an exemption applies;
- it tracks your daily volume, average ticket, receipts and disputes, starts daily monitoring on the 31st day after your first deposit, reviews weekly and re-baselines monthly (§10.4.5.2);
- it must be able to hand Visa your original underwriting package within seven calendar days of a request;
- Visa may disqualify you for reaching a critical level of disputes or acting to circumvent its programs (§10.4.5.4).
Commercially, a reserve may be part of the terms. We don't quote reserve terms because they depend on the file. If an account is terminated, the acquirer can add the merchant to Mastercard's MATCH list, where, as acquirers and vendors describe it, listings stay for five years.
What lowers the risk an underwriter sees?
For a prescription seller, nothing moves the account out of Visa's category, but a good deal changes how it is underwritten inside it. These help:
- LegitScript certification. LegitScript describes it as "a necessary part of the approval process" for card-not-present transactions with Visa and Mastercard. Who is eligible and what it costs is in LegitScript certification for telehealth.
- NABP accreditation, for pharmacies, which removes the Visa merchant-registration step under §1.9.5.1.
- Marketing without "same as" claims, unsupported results or invented testimonials.
- Billing terms visible before payment, with restrictions acknowledged as Visa's §5.4.2.5 requires, and cancellation that works online.
- A descriptor patients recognize, which can head off "I don't recognize this" fraud claims.
- A clean processing history, broken down by dispute reason.
- A complete file, built from the telehealth merchant account application checklist.
Structure matters too. If your pharmacy partner genuinely sells and bills the medication, your account carries the care. That is a real difference in who sells what, not a coding choice, and the underwriter will read the contracts to confirm it.
What doesn't work
Anything that hides what you sell from the people underwriting it. Visa's rules reach each of these:
- A practitioner code on a pharmacy business. Acting to circumvent Visa's programs is grounds for disqualification (§10.4.5.4), and non-compliance with the Visa Integrity Risk Program is grounds for a permanent prohibition (§1.9.1.4).
- Running prescription sales through another company's account. Presenting transactions that don't result from an act between the cardholder and that merchant is laundering in Visa's terms (§1.9.1.4).
- Spreading volume or disputes across extra accounts. That is circumvention of the programs that measure them (§10.4.5.4), and for sponsored merchants Visa can require the acquirer to contract directly with one that acts to evade responsibility for compliance with the rules (§10.4.6.2).
- Re-applying under a new name after termination. Signing a new merchant agreement under a new name to get around the rules is itself listed in §1.9.1.4, and Visa's prohibition can extend to the merchant's principals.
Why it matters who makes the risk decision
Because the party that approves a high-risk account should be the one that can keep it running. VyaPay built its own processor and underwrites risk in-house, with gateway, processing and underwriting on one stack and one risk team, so there is one company between you and the card networks. The team that approves you is the team that keeps you live.
That doesn't mean every telehealth model gets approved; it means the conversation about yours happens once, with the people who decide. If you want to know how your model reads before you apply, talk to VyaPay.
Frequently asked questions
Is an online therapy practice a high-risk merchant?
Not on category alone, in our reading: therapy is a practitioner service under 8099 with no drug sales. Billing model, prepaid packages and dispute history still count.
Does LegitScript certification make a telehealth company low risk?
It doesn't change the category. It is one of the things an underwriter looks for, and LegitScript ties it to card-not-present approval, but a certified merchant selling prescriptions is still a prescription seller.
Will a high-risk telehealth account need a reserve?
It can, depending on prepaid exposure, history and the rest of the file. We don't quote reserve terms in advance.
What happens to controlled-substance telehealth on January 1, 2027?
As of November 2026, the current DEA extension runs through December 31, 2026. Unless DEA acts again, the Ryan Haight Act default of an in-person evaluation, generally required before remote prescribing, applies from January 1, 2027. This is general information, not legal advice.
Sources
- Visa, Visa Core Rules and Visa Product and Service Rules, 24 October 2026 (sections 1.9.1.4, 1.9.5.1, 5.4.2.5, 10.4.5.2, 10.4.5.4)
- Visa, Visa Merchant Data Standards Manual, October 2026 (MCCs 5912, 8099)
- Federal Register, DEA fourth temporary extension of COVID-19 telemedicine flexibilities, December 31, 2025
- Federal Register, DEA proposed rule on special registration for telemedicine, 90 FR 6541, January 17, 2025
- FDA, FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss, content current as of October 1, 2026
- LegitScript, Healthcare Certification FAQ, read November 2026
- Acquirer notices on Mastercard's Specialty Merchant Registration program, and acquirer and vendor summaries of VAMP and MATCH, 2025 to 2026
